LENZ Therapeutics is sharply reducing its workforce and shifting resources toward consumer marketing and sales growth, while arranging a leadership transition. The company also announced its results for the quarter ended Sept. 30, 2026, but the financial figures are not included in the material provided here.
Key details
-
Workforce reduction and spending shift: The board approved a reorganization that will cut headcount by about 75%, leaving approximately 40 full-time employees. LENZ says the plan is intended to prioritize consumer marketing, direct capital toward sales growth and lower operating expenses.
-
Expected costs and timing: The company estimates about $5 million in one-time reorganization charges, primarily severance and related termination benefits. It expects substantially all of the costs to be incurred in the fourth quarter of 2026 and the reorganization to be largely completed by year-end. The estimate could change, and additional costs may arise.
-
CEO transition: Evert Schimmelpennink will step down as president and chief executive on Dec. 1, 2026, and leave the board on that date. Chief Financial Officer Daniel Chevallard will become interim president and CEO.
-
Schimmelpennink’s departure: He will remain a full-time employee through Dec. 31, 2026, serving as strategic adviser to the incoming interim CEO during December. LENZ said his departure was not the result of a dispute with the company.
-
Transition pay and benefits: During the advisory period, Schimmelpennink will continue to receive his annual base salary of $731,400, remain eligible for employee benefits, and continue vesting in outstanding equity awards.
-
Separation payments: If he meets the agreement’s conditions—including remaining employed through Dec. 31, performing his duties in good faith, complying with company agreements and signing required releases—he is eligible for:
- A $731,400 lump-sum payment, equal to 12 months of base salary.
- A $309,016.50 payment for his 2026 annual bonus, calculated using the target bonus and the company’s estimate of corporate-goal achievement.
-
Company-paid health-insurance premiums for him and eligible dependents for up to 12 months after his employment ends.
-
Board size: The board will shrink to five members when Schimmelpennink’s resignation takes effect on Dec. 1.
Plain-English implications
The reorganization is a substantial reduction in LENZ’s workforce, paired with an explicit shift of resources toward consumer marketing and sales. The leadership handoff also places the company’s CFO in the interim CEO role, while Schimmelpennink remains available for a one-month transition period.